Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04950075 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04950075 · ClinicalTrials.gov record · last posted 2026-07-14

Study of INBRX-109 in Conventional Chondrosarcoma

Study acronym: ChonDRAgon
StatusActive, Not Recruiting
PhasePhase 2
Started2021-09-23
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Amendment record 47 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 47 times since 2021-06-30; most recent amendment 2026-07-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-01-07
Status change Recruiting→Active, Not Recruitingv46
2021-10-20
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT04950075
Lead Sponsor Inhibrx Biosciences, Inc
Conditions Conventional Chondrosarcoma
Enrollment 206 participants
Start Date 2021-09-23
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-14